Genotyping Single Nucleotide Polymorphisms

Total Page:16

File Type:pdf, Size:1020Kb

Genotyping Single Nucleotide Polymorphisms REVIEWS ACCESSING GENETIC VARIATION: GENOTYPING SINGLE NUCLEOTIDE POLYMORPHISMS Ann-Christine Syvänen Understanding the relationship between genetic variation and biological function on a genomic scale is expected to provide fundamental new insights into the biology, evolution and pathophysiology of humans and other species. The hope that single nucleotide polymorphisms (SNPs) will allow genes that underlie complex disease to be identified, together with progress in identifying large sets of SNPs, are the driving forces behind intense efforts to establish the technology for large-scale analysis of SNPs. New genotyping methods that are high throughput, accurate and cheap are urgently needed for gaining full access to the abundant genetic variation of organisms. LINKAGE DISEQUILIBRIUM Comparison of genomic DNA sequences in different These SNPs are useful as markers in population 6,7 MAPPING individuals reveals some positions at which two, or in genetics and evolutionary studies . Analysing single nucleotide some cases more than two, bases can occur. These sin- The reason for the current enormous interest in polymorphism alleles in gle nucleotide polymorphisms (SNPs) are highly SNPs is the hope that they could be used as markers to population-based studies to identify loci that are associated abundant, and are estimated to occur at 1 out of every identify genes that predispose individuals to common, 1,2 with a particular disease or 1,000 bases in the human genome . Depending on multifactorial disorders by using LINKAGE DISEQUILIBRIUM phenotype. where a SNP occurs, it might have different conse- (LD) MAPPING8,9. The rationale would be to genotype a quences at the phenotypic level. SNPs in the coding collection of SNPs that occur at regular intervals and regions of genes that alter the function or structure of cover the whole genome to detect genomic regions in the encoded proteins are a necessary and sufficient which the frequencies of the SNP alleles differ between cause of most of the known recessively or dominantly patients and controls. It is assumed that the SNP alleles inherited monogenic disorders. These SNPs are rou- are inherited together with the disease-predisposing tinely analysed for diagnostic purposes. Another alleles through the generations because they are physi- important group of SNPs are those that alter the pri- cally close to each other. The disease-predisposing mary structure of a protein involved in drug metabo- genes could then be localized and isolated, and pro- lism. These SNPs are targets for pharmacogenetic teins encoded by them would be valuable targets for analyses3. Missense SNPs in the coding regions of developing new therapeutic drugs. As a result of the genes, such as the two SNPs in the apolipoprotein E efforts of the SNP Consortium — a collaboration of gene4 and the factor V Leiden mutation5, can also con- 14 major pharmaceutical companies and the Department of tribute to common disease. This type of SNP can be Wellcome Trust, as well as members of the Human Medical Sciences — analysed to assess the risk of an individual for a par- Genome Project1 — there are almost 2 million SNPs in Molecular Medicine, ticular disease. In addition, it is likely that SNPs in the public databases, and perhaps twice that number of Uppsala University, regulatory regions of genes might influence the risk of SNPs in commercial databases, such as that of Celera University Hospital, 2 75185 Uppsala, Sweden. common disease. However, most SNPs are located in Genomics . The SNPs are now being verified experi- e-mail: Ann-Christine. non-coding regions of the genome, and have no direct mentally, and their distributions between and within [email protected] known impact on the phenotype of an individual. populations are being assessed10,11. 930 | DECEMBER 2001 | VOLUME 2 www.nature.com/reviews/genetics © 2001 Macmillan Magazines Ltd REVIEWS Table 1 | Recent or large studies involving SNP genotyping Purpose of study No. of No. of No. of Method SNPs samples genotypes SNPs in the ACE gene131 13 1,300 17,000 Restriction-site analysis NOD2 gene in Crohn disease132 13 1,300 17,000 Invader115 and TaqMan50 assays Mapping complex disease traits 109 299 33,000 Allele-specific PCR60 in mice34 Sequence diversity of 20 2,200 44,000 Oligonucleotide ligation assay95 the APOE gene133 APOE haplotypes in 60 1,000 60,000 TaqMan assay50 Alzheimer disease32 Ancestral alleles of 214 412 99,000 GeneChip39 human SNPs7 Carrier frequencies of 31 4,400 140,000 Primer extension on microarrays82 disease mutations134 Haplotype tagging in 122 1,500 180,000 Invader PCR assay115 diabetes candidate genes135 Linkage disequilibrium 312 681 210,000 Multiplex primer extension69,71,137 in the 5q31 region136 ACE, angiotensin I-converting enzyme (peptidyl-dipeptidase A)1; APOE, apolipoprotein E; SNP, single nucleotide polymorphism. But how many SNPs are needed? Although recent these routine applications is now available20, although studies indicate that LD is structured into discrete these fields would obviously benefit from lower genotyp- blocks in the human genome12,13, the range and distrib- ing costs. TABLE 1 gives some examples of recent or large ution of LD in different populations is largely unknown. studies in which SNP genotyping had a fundamental role. Furthermore, the effect of genotype on disease pheno- The scale of these projects is modest, and it is certain that type varies between disorders and populations owing to larger studies that have not been published have been genetic and environmental heterogeneity14. For these conducted, or are in progress, in the commercial sector. reasons, it is difficult to estimate the number of SNPs or Key targets to improve SNP genotyping technology the number of samples that would be required for a suc- are cost, simplicity of assay design, throughput and cessful genome-wide LD study. The estimates that have accuracy. One approach for increasing throughput is to been made vary widely, from 1 million15 or 0.5 million16 devise automated assay formats of the generally used to as little as 30,000 SNPs17. If 0.5 million SNPs were to reaction principles for genotyping individual SNPs, and be analysed in, for example, 1,000 individuals, and if the to use a ‘brute force’ strategy by multiplying these auto- project was to be carried out in a year, ~1.5 million SNP mated platforms. This strategy is analogous to the genotypes per day would be produced. At genotyping implementation of Sanger’s dideoxy method for DNA costs as low as US 10 cents per SNP,this example project sequencing21 by the Human Genome Project2,22.A sec- would cost US $50 million. The throughput required ond approach to increase throughput is to multiplex the for this project, which comprises only a modest number biochemical genotyping reactions, instead of the plat- of samples, is about 100-fold greater than the capacity of forms. Microarray technology is a typical example of SNP-genotyping technology available now. Both the this approach. The most challenging approach is to costs and the throughput would prohibit executing the develop completely new molecular strategies for SNP project in even the largest genotyping centres. For typ- genotyping. In this article, I review the current state of ing 30,000 SNPs in 1,000 individuals in a year, about a the art of SNP-genotyping technology, with an empha- tenfold increase in the capabilities of current technology sis on how amenable the different methods are to multi- would be enough. plexing to increase throughput and bring down the A more feasible alternative to random whole-genome costs of the assays. Several promising new principles and SNP mapping is to use SNP markers in or close to candi- assay formats also discussed. date genes, or in candidate genomic regions. For example, the genotyping of 20 SNPs in 50 candidate genes (1,000 Principles of SNP-genotyping methods SNPs) or of 1 SNP per 10 kb in a 10-million-bp candidate The ability of hybridization with allele-specific genomic region in 1,000 samples represents a reasonable oligonucleotides (ASO) to detect a single base mis- goal of 1 million genotypes. It would be possible to carry match was first shown in 1979 (REF. 23), and then used out a project of this size within a few months in an inter- to detect the sickle-cell mutation in the β-globin gene mediate-sized genotyping centre equipped with modern by Southern blot hybridization to human genomic SNP-genotyping technology. For diagnosis and carrier DNA in 1983 (REF. 24). Identification of a single base screening of monogenic disorders and for routine phar- change in the 6 × 109 bp of the diploid human genome macogenetic applications, tens of SNPs are typically is, however, a demanding task. Not until the PCR tech- analysed in several thousand samples3,18,19. SNP-genotyp- nique was invented25,26, did it become possible to ing technology with acceptable throughput and cost for design useful assays for genotyping SNPs in complex NATURE REVIEWS | GENETICS VOLUME 2 | DECEMBER 2001 | 931 © 2001 Macmillan Magazines Ltd REVIEWS REVERSE DOT BLOT genomes. BOX 1 summarizes six central biochemical PCR technique was developed further by several A genotyping method based on reaction principles that underlie SNP-genotyping groups to allow allele-specific amplification and geno- hybridization between allele- methods, and FIG. 1 illustrates how some of the current typing of SNPs31. The use of ASOs as hybridization specific oligonucleotide probes SNP-genotyping platforms have been devised by com- probes or as PCR primers is the basis for the SNP- that have been immobilized on a membrane, and amplified bining a reaction principle with an assay format and a genotyping assays that are referred to as ‘homogeneous’, DNA fragments in solution. detection strategy. because they contain no separation steps and are moni- Some of the early SNP-genotyping assays used for tored in real time during PCR.
Recommended publications
  • Snps in Forensic Genetics: a Review on SNP Typing Methodologies Beatriz Sobrinoa,B,*, Marı´A Brio´Na,B, Angel Carracedoa,B
    Forensic Science International 154 (2005) 181–194 www.elsevier.com/locate/forsciint SNPs in forensic genetics: a review on SNP typing methodologies Beatriz Sobrinoa,b,*, Marı´a Brio´na,b, Angel Carracedoa,b aInstitute of Legal Medicine, University of Santiago de Compostela, San Francisco s/n, 15782 Santiago de Compostela, Spain bNational Genotyping Center (CeGen), University of Santiago de Compostela, Hospital Clı´nico Universitario, 15706 Santiago de Compostela, Spain Received 8 June 2004; received in revised form 10 October 2004; accepted 15 October 2004 Available online 11 January 2005 Abstract There is an increasing interest in single nucleotide polymorphism (SNP) typing in the forensic field, not only for the usefulness of SNPs for defining Y chromosome or mtDNA haplogroups or for analyzing the geographical origin of samples, but also for the potential applications of autosomal SNPs. The interest of forensic researchers in autosomal SNPs has been attracted due to the potential advantages in paternity testing because of the low mutation rates and specially in the analysis of degraded samples by use of short amplicons. New SNP genotyping methods, chemistries and platforms are continuously being developed and it is often difficult to be keeping up to date and to decide on the best technology options available. This review offers to the reader a state of the art of SNP genotyping technologies with the advantages and disadvantages of the different chemistries and platforms for different forensic requirements. # 2004 Elsevier Ireland Ltd. All rights reserved. Keywords: Single nucleotide polymorphism (SNP); SNP genotyping; DNA typing; Forensic genetics 1. Introduction since they can be used as markers to identify the genes that underlie complex diseases and to realize the full potential of Single nucleotide polymorphisms (SNPs) represent the pharmacogenomics in analyzing variable response to drugs.
    [Show full text]
  • GENOME GENERATION Glossary
    GENOME GENERATION Glossary Chromosome An organism’s DNA is packaged into chromosomes. Humans have 23 pairs of chromosomesincluding one pair of sex chromosomes. Women have two X chromosomes and men have one X and one Y chromosome. Dominant (see also recessive) Genes come in pairs. A dominant form of a gene is the “stronger” version that will be expressed. Therefore if someone has one dominant and one recessive form of a gene, only the characteristics of the dominant form will appear. DNA DNA is the long molecule that contains the genetic instructions for nearly all living things. Two strands of DNA are twisted together into a double helix. The DNA code is made up of four chemical letters (A, C, G and T) which are commonly referred to as bases or nucleotides. Gene A gene is a section of DNA that is the code for a specific biological component, usually a protein. Each gene may have several alternative forms. Each of us has two copies of most of our genes, one copy inherited from each parent. Most of our traits are the result of the combined effects of a number of different genes. Very few traits are the result of just one gene. Genetic sequence The precise order of letters (bases) in a section of DNA. Genome A genome is the complete DNA instructions for an organism. The human genome contains 3 billion DNA letters and approximately 23,000 genes. Genomics Genomics is the study of genomes. This includes not only the DNA sequence itself, but also an understanding of the function and regulation of genes both individually and in combination.
    [Show full text]
  • Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
    pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient.
    [Show full text]
  • HIV Genotyping and Phenotyping AHS – M2093
    Corporate Medical Policy HIV Genotyping and Phenotyping AHS – M2093 File Name: HIV_genotyping_and_phenotyping Origination: 1/2019 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Description Human immunodeficiency virus (HIV) is an RNA retrovirus that infects human immune cells (specifically CD4 cells) causing progressive deterioration of the immune system ultimately leading to acquired immune deficiency syndrome (AIDS) characterized by susceptibility to opportunistic infections and HIV-related cancers (CDC, 2014). Related Policies Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection Scientific Background Human immunodeficiency virus (HIV) targets the immune system, eventually hindering the body’s ability to fight infections and diseases. If not treated, an HIV infection may lead to acquired immunodeficiency syndrome (AIDS) which is a condition caused by the virus. There are two main types of HIV: HIV-1 and HIV-2; both are genetically different. HIV-1 is more common and widespread than HIV-2. HIV replicates rapidly; a replication cycle rate of approximately one to two days ensures that after a single year, the virus in an infected individual may be 200 to 300 generations removed from the initial infection-causing virus (Coffin & Swanstrom, 2013). This leads to great genetic diversity of each HIV infection in a single individual. As an RNA retrovirus, HIV requires the use of a reverse transcriptase for replication purposes. A reverse transcriptase is an enzyme which generates complimentary DNA from an RNA template. This enzyme is error-prone with the overall single-step point mutation rate reaching ∼3.4 × 10−5 mutations per base per replication cycle (Mansky & Temin, 1995), leading to approximately one genome in three containing a mutation after each round of replication (some of which confer drug resistance).
    [Show full text]
  • Review of the Current State of Genetic Testing - a Living Resource
    Review of the Current State of Genetic Testing - A Living Resource Prepared by Liza Gershony, DVM, PhD and Anita Oberbauer, PhD of the University of California, Davis Editorial input by Leigh Anne Clark, PhD of Clemson University July, 2020 Contents Introduction .................................................................................................................................................. 1 I. The Basics ......................................................................................................................................... 2 II. Modes of Inheritance ....................................................................................................................... 7 a. Mendelian Inheritance and Punnett Squares ................................................................................. 7 b. Non-Mendelian Inheritance ........................................................................................................... 10 III. Genetic Selection and Populations ................................................................................................ 13 IV. Dog Breeds as Populations ............................................................................................................. 15 V. Canine Genetic Tests ...................................................................................................................... 16 a. Direct and Indirect Tests ................................................................................................................ 17 b. Single
    [Show full text]
  • Evaluation of Openarray™ As a Genotyping Method for Forensic DNA Phenotyping and Human Identification
    G C A T T A C G G C A T genes Article Evaluation of OpenArray™ as a Genotyping Method for Forensic DNA Phenotyping and Human Identification Michele Ragazzo 1, Giulio Puleri 1, Valeria Errichiello 1, Laura Manzo 1, Laura Luzzi 1 , Saverio Potenza 2 , Claudia Strafella 1,3 , Cristina Peconi 3, Fabio Nicastro 4 , Valerio Caputo 1 and Emiliano Giardina 1,3,* 1 Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy; [email protected] (M.R.); [email protected] (G.P.); [email protected] (V.E.); [email protected] (L.M.); [email protected] (L.L.); [email protected] (C.S.); [email protected] (V.C.) 2 Department of Biomedicine and Prevention, Section of Legal Medicine, Social Security and Forensic Toxicology, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] 3 Genomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy; [email protected] 4 Austech, 00153 Rome, Italy; [email protected] * Correspondence: [email protected] Abstract: A custom plate of OpenArray™ technology was evaluated to test 60 single-nucleotide polymorphisms (SNPs) validated for the prediction of eye color, hair color, and skin pigmentation, and for personal identification. The SNPs were selected from already validated subsets (Hirisplex-s, Precision ID Identity SNP Panel, and ForenSeq DNA Signature Prep Kit). The concordance rate and call rate for every SNP were calculated by analyzing 314 sequenced DNA samples. The sensitivity of the assay was assessed by preparing a dilution series of 10.0, 5.0, 1.0, and 0.5 ng.
    [Show full text]
  • Genotyping-By-Sequencing to Unlock Genetic Diversity and Population Structure in White Yam (Dioscorea Rotundata Poir.)
    agronomy Article Genotyping-by-Sequencing to Unlock Genetic Diversity and Population Structure in White Yam (Dioscorea rotundata Poir.) Ranjana Bhattacharjee 1,* , Paterne Agre 1 , Guillaume Bauchet 2, David De Koeyer 3, Antonio Lopez-Montes 1,4, P. Lava Kumar 1 , Michael Abberton 1, Patrick Adebola 5, Asrat Asfaw 5 and Robert Asiedu 1 1 International Institute of Tropical Agriculture, PMB 5320, Ibadan 200001, Nigeria; [email protected] (P.A.); [email protected] (A.L.-M.); [email protected] (P.L.K.); [email protected] (M.A.); [email protected] (R.A.) 2 Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA; [email protected] 3 Agriculture and Agri-Food Canada, Fredericton, NB E3B 4Z7, Canada; [email protected] 4 International Trade Center, 29 Independence Avenue, Accra 00233, Ghana 5 International Institute of Tropical Agriculture, PMB 82, Kubuwa, Abuja 901101, Nigeria; [email protected] (P.A.); [email protected] (A.A.) * Correspondence: [email protected] Received: 7 August 2020; Accepted: 14 September 2020; Published: 22 September 2020 Abstract: White yam (Dioscorea rotundata Poir.) is one of the most important tuber crops in West Africa, where it is indigenous and represents the largest repository of biodiversity through several years of domestication, production, consumption, and trade. In this study, the genotyping-by-sequencing (GBS) approach was used to sequence 814 genotypes consisting of genebank landraces, breeding lines, and market varieties to understand the level of genetic diversity and pattern of the population structure among them. The genetic diversity among different genotypes was assessed using three complementary clustering methods, the model-based admixture, discriminant analysis of principal components (DAPC), and phylogenetic tree.
    [Show full text]
  • DNA Phenotyping and Kinship Determination
    DNA Phenotyping and Kinship Determination Ellen McRae Greytak, PhD Director of Bioinformatics Parabon NanoLabs, Inc. ©©2 2015015 ParabonParabon NanoLabs,NanoLabs Inc.Inc All rightsrights reserved. reserved Forensic Applications of DNA Phenotyping Predict a person’s ancestry and/or appearance (“phenotype”) from his or her DNA Generate investigative leads when DNA doesn’t match a database (e.g., CODIS) Gain additional information (e.g., pigmentation, detailed ancestry) about unidentified remains Main value is in excluding non-matching individuals to help narrow a suspect list Without information on age, weight, lifestyle, etc., phenotyping currently is not targeted toward individual identification Snapshot Workflow Workflow of a Parabon® Snapshot™ Investigation Unidentified Remains DNA Evidence Is Collected and Sent to Crime Lab DNA Evidence DNA Crime Lab CCrime Lab Extracts DNA And Produces STR Profile Checked STR Profile (a.k.a. “DNA Fingerprint”) AAgainst DNA Database(s) Yes Match No Found? SnapshotS Composite Ordered Extracted DNA ™ D N A PH E N O T Y P I N G DNA Service Labs Unidentified DNA Is Genotype Data Is Genotyping Lab Produces SNP Sent To Service Lab Sent To Parabon Profile (a.k.a. “DNA Blueprint”) (DNA Extracted If Needed) 50pg – 2ng DNA Evidence — or — Extracted DNA NOTE: STR Profiles Do Not Contain Sufficient Genetic Information to Produce A SNP Genotype Parabon NanoLabs PParabonb AnalyzesAl PParabon Predicts Physical Traits Investigator Uses Genotype Data and Produces Snapshot Report
    [Show full text]
  • Genotyping of Single Nucleotide Polymorphisms Using Allele
    diagnostics Article Genotyping of Single Nucleotide Polymorphisms Using Allele-Specific qPCR Producing Amplicons of Small Sizes Directly from Crude Serum Isolated from Capillary Blood by a Hand-Powered Paper Centrifuge Gustavo Barcelos Barra 1,2,*,† , Ticiane Henriques Santa Rita 1,2,†, Daniella Paniago Jardim 1,2,†, Pedro Góes Mesquita 1, Camila Santos Nobre 1,2, Rafael Henriques Jácomo 1 and Lídia Freire Abdalla Nery 1 1 Sabin Laboratory, Brasília 70632-300, Brazil; [email protected] (T.H.S.R.); [email protected] (D.P.J.); [email protected] (P.G.M.); [email protected] (C.S.N.); [email protected] (R.H.J.); [email protected] (L.F.A.N.) 2 Post-Graduation of Health Science, University of Brasília, Brasilia 70910-900, Brazil * Correspondence: [email protected] † These authors contributed equally to the study. Received: 15 November 2018; Accepted: 29 December 2018; Published: 11 January 2019 Abstract: The cell-free genomic DNA (gDNA) concentration in serum ranges from 1500 to 7500 copies/mL within 2 h after phlebotomy (6–24 times the concentration observed in plasma). Here, we aimed to evaluate the gDNA size distribution in serum with time after coagulation and to test if crude serum can be directly used as a source of gDNA for qPCR. Next, we investigated if single nucleotide polymorphisms (SNPs) could be genotyped directly from the crude serum isolated from capillary blood using a hand-powered paper centrifuge. All tested PCR targets (65, 100, 202 and 688 base pairs) could be successfully amplified from DNA extracted from serum, irrespective of their amplicon size.
    [Show full text]
  • Molecular Methods for Bacterial Genotyping and Analyzed Gene Regions
    42Journal of Microbiology and Infectious DiseasesYıldırım / İH et al. Molecular methods 2011; 1 (1): 42-46 JMID doi: 10.5799/ahinjs.02.2011.01.0011 REVIEW ARTICLE Molecular methods for bacterial genotyping and analyzed gene regions İbrahim Halil Yıldırım1, Seval Cing Yıldırım2, Nadir Koçak3 1Dicle University, Faculty of Veterinary Department of Genetics, Diyarbakır, Turkey 2İnönü University, Faculty of Science, Department of Biology, Malatya, Turkey 3Selçuk University, Selçuklu Medical Faculty, Department of Medical Genetics, Konya, Turkey ABSTRACT Bacterial strain typing is an important process for diagnosis, treatment and epidemiological investigations. Current bacterial strain typing methods may be classified into two main categories: phenotyping and genotyping. Phenotypic characters are the reflection of genetic contents. Genotyping, which refers discrimination of bacterial strains based on their genetic content, has recently become widely used for bacterial strain typing. The methods already used in geno- typing of bacteria are quite different from each other. In this review we tried to summarize the basic principles of DNA- based methods used in genotyping of bacteria and describe some important DNA regions that are used in genotyping of bacteria. J Microbiol Infect Dis 2011;1(1):42-46. Key words: Bacterial genotyping, pulsed-field gel electrophoresis, internal transcribed region (ITS) Bakteri genotiplendirmesinde kullanılan moleküler yöntemler ve incelenen gen bölgeleri ÖZET Bakteri tiplendirilmesi tanı, tedavi ve epidemiyolojik araştırmalar için önemli bir süreçtir. Mevcut bakteriyal suş tiplendir- me yöntemleri iki ana kategoride sınıflandırılabilir: fenotipleme ve genotipleme. Fenotipik karakterler genetik içeriğin yansımasıdır. Bakterilerin genetik içeriklerine bağlı olarak sınıflandırılması olan genotiplendirme son dönemlerde bak- teri tiplendirmesinde sıklıkla kullanılmaktadır. Bakteri genotiplendirmesinde kullanılan yöntemler birbirlerinden oldukça farklıdır.
    [Show full text]
  • Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling
    Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) January 2013 Clinical Pharmacology Clinical/Medical 10300.fnl.doc Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 10903 New Hampshire Ave. Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax 301-847-8714 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach, and Development (HFM-40) Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (Tel) 800-835-4709 or 301-827-1800 or Office of Communication, Education, and Radiation Programs Division of Small Manufacturers, International and Consumer Assistance Center for Devices and Radiological Health Food and Drug Administration 10903 New Hampshire Ave. WO66, Room 4613 Silver Spring, MD 20993-0002 http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm Email: [email protected] Fax: 301-827-8149 (Tel) Manufacturers Assistance: 800-638-2041 or 301-796-7100 (Tel) International Staff: 301-796-5708 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) January 2013 Clinical Pharmacology Clinical/Medical TABLE OF CONTENTS I.
    [Show full text]
  • Genotyping Bacterial and Fungal Pathogens Using Sequence Variation in the Gene for the CCA-Adding Enzyme Paul Franz, Heike Betat and Mario Mörl*
    Franz et al. BMC Microbiology (2016) 16:47 DOI 10.1186/s12866-016-0670-2 METHODOLOGY ARTICLE Open Access Genotyping bacterial and fungal pathogens using sequence variation in the gene for the CCA-adding enzyme Paul Franz, Heike Betat and Mario Mörl* Abstract Background: To allow an immediate treatment of an infection with suitable antibiotics and bactericides or fungicides, there is an urgent need for fast and precise identification of the causative human pathogens. Methods based on DNA sequence comparison like 16S rRNA analysis have become standard tools for pathogen verification. However, the distinction of closely related organisms remains a challenging task. To overcome such limitations, we identified a new genomic target sequence located in the single copy gene for tRNA nucleotidyltransferase fulfilling the requirements for a ubiquitous, yet highly specific DNA marker. In the present study, we demonstrate that this sequence marker has a higher discriminating potential than commonly used genotyping markers in pro- as well as eukaryotes, underscoring its applicability as an excellent diagnostic tool in infectology. Results: Based on phylogenetic analyses, a region within the gene for tRNA nucleotidyltransferase (CCA-adding enzyme) was identified as highly heterogeneous. As prominent examples for pro- and eukaryotic pathogens, several Vibrio and Aspergillus species were used for genotyping and identification in a multiplex PCR approach followed by gel electrophoresis and fluorescence-based product detection. Compared to rRNA analysis, the selected gene region of the tRNA nucleotidyltransferase revealed a seven to 30-fold higher distinction potential between closely related Vibrio or Aspergillus species, respectively. The obtained data exhibit a superb genome specificity in the diagnostic analysis.
    [Show full text]